WO2005089080A3 - Method and kit for screening, pharmaceutical compositions and method for treatment of autoimmune disorders - Google Patents

Method and kit for screening, pharmaceutical compositions and method for treatment of autoimmune disorders Download PDF

Info

Publication number
WO2005089080A3
WO2005089080A3 PCT/SE2005/000414 SE2005000414W WO2005089080A3 WO 2005089080 A3 WO2005089080 A3 WO 2005089080A3 SE 2005000414 W SE2005000414 W SE 2005000414W WO 2005089080 A3 WO2005089080 A3 WO 2005089080A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
runx2
runx1
pdcd1
runx3
Prior art date
Application number
PCT/SE2005/000414
Other languages
French (fr)
Other versions
WO2005089080A2 (en
Inventor
Marta E Alarcon-Riquelme
Ludmila Prokunina
Sergey Kozyrev
Original Assignee
Marta E Alarcon-Riquelme
Ludmila Prokunina
Everygene Ab
Sergey Kozyrev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marta E Alarcon-Riquelme, Ludmila Prokunina, Everygene Ab, Sergey Kozyrev filed Critical Marta E Alarcon-Riquelme
Publication of WO2005089080A2 publication Critical patent/WO2005089080A2/en
Publication of WO2005089080A3 publication Critical patent/WO2005089080A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a method for screening and/or diagnosis of autoimmune disorders comprising the step of : a) obtaining biological sample from a test subject b) contacting the biological sample with at least one agent capable of detecting at least one of PDCD1, RUNX1, RUNX2 and/or RUNX3 nucleic acid or the corresponding expression product coded for by one or more of these genes or a subfragment thereof. d) comparing the expression rate of at least one expression product from PDCD1, RUNX1, RUNX2 and/or RUNX3 nucleic acid or a subfragment thereof from a healthy test subject with the expression rate thereof from another test subject. The invention also relates to a kit, a method for identifying compounds, that modulate PDCD1, RUNX1, RUNX2 or RUNX3 expression, a pharmaceutical composition comprising such a compound, the use of such a composition for the preparation of a pharmaceutical composition for the treatment of autoimmune diseases and a method for the treatment of a patient suffering from an autoimmune disease. The invention especially relates to systemic lupus erythematosus (SLE) and rheumatoid arthritis.
PCT/SE2005/000414 2004-03-22 2005-03-22 Method and kit for screening, pharmaceutical compositions and method for treatment of autoimmune disorders WO2005089080A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55517904P 2004-03-22 2004-03-22
US60/555,179 2004-03-22

Publications (2)

Publication Number Publication Date
WO2005089080A2 WO2005089080A2 (en) 2005-09-29
WO2005089080A3 true WO2005089080A3 (en) 2005-11-17

Family

ID=34994135

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2005/000414 WO2005089080A2 (en) 2004-03-22 2005-03-22 Method and kit for screening, pharmaceutical compositions and method for treatment of autoimmune disorders

Country Status (1)

Country Link
WO (1) WO2005089080A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018084706A1 (en) * 2016-11-04 2018-05-11 Erasmus University Medical Center Rotterdam Markers for identifying patient classes and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022875A2 (en) * 2001-09-07 2003-03-20 Everygene Ab Polymorphisms of pd-1
US20030232323A1 (en) * 2001-11-13 2003-12-18 Wyeth Agents that modulate immune cell activation and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022875A2 (en) * 2001-09-07 2003-03-20 Everygene Ab Polymorphisms of pd-1
US20030232323A1 (en) * 2001-11-13 2003-12-18 Wyeth Agents that modulate immune cell activation and methods of use thereof

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALARCON-RIQUELME M.E. ET AL: "A runx trio with a taste for autoimmunity", NATURE GENETICS, vol. 35, no. 4, December 2003 (2003-12-01), pages 299 - 300, XP002991618 *
ALARCON-RIQUELME M.E. ET AL: "Finding genes for SLE: complex interactions and complex populations", JOURNAL OF AUTOIMMUNITY, vol. 21, 2003, pages 17 - 20, XP002991619 *
DATABASE GENBANK [online] 2 July 2003 (2003-07-02), XP002991615, accession no. NCBI Database accession no. (AX770853) *
HATACHI S. ET AL: "DC4+ PD-1+ T Cells Accumulate as Unique Anergic Cells in Rheumatoid Arthritis Synovial Fluid", J RHEUMATOL, vol. 30, 2003, pages 1410 - 1419, XP008053453 *
NIELSEN C. ET AL: "Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes", TISSUE ANTIGENS, vol. 62, no. 6, December 2003 (2003-12-01), pages 492 - 497, XP002991620 *
NISHIMURA H. ET AL: "Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor", IMMUNITY, vol. 11, August 1999 (1999-08-01), pages 141 - 151, XP000971788 *
PROKUNINA L. ET AL: "A regulatory polyorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans", NATURE GENETICS, vol. 32, December 2002 (2002-12-01), pages 666 - 669, XP002243477 *
PROKUNINA L. ET AL: "The genetic basis of systemic lupus erythematosus-knowledge of today and thoughts for tomorrow", HUMAN MOLECULAR GENETICS, vol. 13, no. 1, 2004, pages R143 - R148, XP002991616 *
TOKUHIRO S. ET AL: "An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transorter, is associated with rheumatoid arthritis", NATURE GENETICS, vol. 35, no. 4, December 2003 (2003-12-01), pages 341 - 348, XP002991617 *

Also Published As

Publication number Publication date
WO2005089080A2 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
Peralta et al. Factor structure of symptoms in functional psychoses
WO2009132058A3 (en) Levels of bcma protein expression on b cells and use in diagnostic methods
Müller et al. Phenotype of matrin‐3–related distal myopathy in 16 G erman patients
Assoum et al. Rundataxin, a novel protein with RUN and diacylglycerol binding domains, is mutant in a new recessive ataxia
Mariani et al. Expanding the spectrum of genes involved in Huntington disease using a combined clinical and genetic approach
EP2302079A3 (en) Systemic lupus erythematosus diagnostic assay
WO2005108989A3 (en) Assay for antibodies
WO2003085095A3 (en) Novel expressed genes
WO2006081521A3 (en) Methods for diagnosis and intervention of hepatic disorders
WO2011094535A2 (en) Biomarkers of aging for detection and treatment of disorders
WO2006044748A3 (en) RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
TW200636076A (en) Method for measuring resistance or sensitivity to docetaxel
WO2009077864A3 (en) Compositions and methods of detecting tiabs
Nam et al. Wide phenotypic spectrum in axonal Charcot–Marie–Tooth neuropathy type 2 patients with KIF5A mutations
WO2004024941A3 (en) Biochemical methods for measuring metabolic fitness of tissues or whole organisms
WO2007016532A3 (en) Mutations and polymorphisms of hdac4
EP2365335A3 (en) Diagnostic method
ATE467834T1 (en) OLIGOSACCHARIDE BIOMARKERS FOR MUCOPOLYSACCHARIDOSES AND OTHER RELATED DISORDERS
DE602004024539D1 (en) METHOD AND SYSTEMS FOR DIAGNOSIS OF NON-DISTRACTIVE CNS DISEASES IN CNS SAMPLES
WO2006099543A3 (en) Methods for assessing antibody-mediated cytotoxicity
Kim et al. Association of the OSCAR promoter polymorphism with BMD in postmenopausal women
Todorovic et al. Frailty index and phenotype frailty score: sex-and age-related differences in 5XFAD transgenic mouse model of Alzheimer’s disease
WO2008082519A3 (en) Screening for cd93 (c1qrp)-associated polymorphism(s) in the diagnosis, prevention and treatment of autoimmune diseases
AU2003296424A1 (en) Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders
Shalata et al. Myotonia congenita in a large consanguineous Arab family: insight into the clinical spectrum of carriers and double heterozygotes of a novel mutation in the chloride channel CLCN1 gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase